REG - Spectral MD Holdings - Removal of Regulation S restrictions

Spectral MD HoldingsAnnouncement

23/06/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220623:nRSW6885Pa&default-theme=true

RNS Number : 6885P  Spectral MD Holdings, Ltd.  23 June 2022

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company")

 

Removal of Regulation S restrictions from shares of common stock

 

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company that develops proprietary AI algorithms and
optical technology for faster and more accurate treatment decisions in wound
care, announces that restrictive legends have today been removed from the
Company's 136,097,064 shares of common stock of US$0.001 each of the Company
("Common Stock"). The Common Stock was previously 'Regulation S' stock and
restricted as defined in Rule 144 of the US Securities Act of 1933.

 

The Company's line of Common Stock with ISIN number USU8457V1099 is now
unrestricted, save for shares held by certain controlling shareholders
(principally the Directors and officers) and affiliates of the Company who
will be required to maintain certain restrictions.

 

Spectral has no Common Stock in treasury, therefore 136,097,064 may be used
by shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change in
their interest in, the share capital of the Company under the Company's
Certificate of Incorporation.

 

For further information please contact:

 

 Spectral MD Holdings, Ltd.                                                           investors.spectralmd.com
 Wensheng Fan, Chief Executive Officer                                                via Walbrook PR
 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (NOMAD and Joint Broker)                              Tel: +44 (0)20 3470 0470
 Stuart Gledhill/Caroline Rowe (Corporate Finance)


 Vadim Alexandre/Rob Rees (Sales & Broking)

 Stifel Nicolaus Europe Limited (Joint Broker)                                        Tel: +44 (0) 20 7710 7600

 Charles Hoare / Ben Maddison / Nick Harland / Will Palmer-Brown

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
 Paul McManus / Sam Allen                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 Alice Woodings                                    +44 (0)7407 804 654

 

 

About Spectral MD:
 

We are a dedicated team of forward-thinkers striving to revolutionize the
management of wound care by "Seeing the Unknown" ® with our DeepView(®)
Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGZGZVKMRGZZM